Candidiasis emerging species under antibiotic treatment: Clinical impact;Émergence des levures de type Candida sous antibiotiques: Impact clinique

Medecine/Sciences

Volumn 24, Issue SUPPL. 3, 2008, Pages 24-31

  Ribadeau Dumas, Florence ^a   Bougnoux, Marie Elisabeth ^a   Zahar, Jean Ralph ^a   Lortholary, Olivier ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; ERTAPENEM; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; METRONIDAZOLE; NORFLOXACIN; OFLOXACIN; OXAZOLIDINE DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SULTAMICILLIN; TIGECYCLINE; TIMENTIN; VANCOMYCIN;

ANAEROBE; ANTIMICROBIAL THERAPY; CANDIDA; CANDIDIASIS; COMMENSAL; DRUG EFFICACY; EUROPE; FUNGAL COLONIZATION; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INCIDENCE; INTESTINE FLORA; INVASIVE CANDIDIASIS; MORTALITY; MUCOSA; MYCOSIS; NONHUMAN; PRESCRIPTION; REVIEW; RISK FACTOR; VAGINA CANDIDIASIS;

ANIMALIA; CANDIDA;

EID: 51949093600     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2008243s24     Document Type: Review

References (65)

1. Pfaller MA. Nosocomial candidiasis : emerging species, reservoirs and modes of transmission. Clin Infect Dis 1996 ; 22 : 89-94.
2. Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of candidemia in Europe : Results of 28-month European Confederation of Medical Mycology hospital-based surveillance study. Eur J Clin Infect Dis 2004 ; 23 : 317-22.
3. Soll DR, Galask R, Schmid J, et al. Genetic dissimilarity of commensal strains of Candida spp. carried in different anatomical locations of the same healthy women. J Clin Microbiol 1991 ; 29 : 1702-10.
4. Wade, W. Epidemiology of Candida infection. In : Bodey GP, ed. Candidiasis : pathogenesis, diagnosis, and treatment. New York : Raven Press, 1993 : 85-107.
5. Fong, I. The rectal carriage in patients with vaginal candidiasis. Clin Invest Med 1994 ; 17 : 426-31.
6. Odds FC. Candida and candidiasis. Philadelphia, PA : W.B. Saunders Co, 1998.
7. Xu JC, Boyd M, Livingston E, et al. Species and genotypic diversities and similarities of pathogenic yeasts colonizing women. J Clin Microbiol 1999 ; 37 : 3835-43.
8. Kam AP, Xu J. Diversity of commensal yeasts within and among healthy hosts. Diagn Microbiol Infect Dis 2002 ; 43 : 19-28.
9. Bougnoux ME, Diogo D, François N, et al. Multilocus sequence typing reveals intrafamilial transmission and microevalutions of Candida albicans isolates from the human digestive tract. J Clin Microbiol 2006 ; 44 : 1810-20.
10. Kleinegger CL, Lockhart SR, Vargas K, Soll DR. Frequency, intensity, species, and strains of oral Candida vary as a function of host age. J Clin Microbiol 1996 ; 34 : 2246-54.
11. Strausbaugh L, Sewell D, Ward TT, et al. High frequency of yeast carriage on hands of hospital personnel. J Clin Microbiol 1994 ; 32 : 2299-30.
12. Huang YC, Lin TY, Leu HS, et al. Yeast carriage on hands of hospital personnel working in intensive care units. J Hosp Infect 1998 ; 39 : 47-51.
13. Safdar A, Chaturvedi V, Cross EW, et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 2001 ; 45 : 2129-33.
14. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003 ; 3 : 685-702.
15. Balish E, Phillips AW. Growth and virulence of Candida albicans after oral inoculation in the chick with a monoflora of either Escherichia coli or Streptococcus faecalis. J Bacteriol 1966 ; 91 : 1744-9.
16. Balish E, Phillips AW. Growth, morphogenesis, and virulence of Candida albicans after oral inoculation in the germ-free and conventional chick. J Bacteriol 1966 ; 91 : 1736-43.
17. Syed SA, Abrams GD, Freter R. Efficiency of various intestinal bacteria in assuming normal functions of enteric flora after association with germ-free mice. Infect Immun 1970 ; 2 : 376-86.
18. Hummel RP, Maley MP, Miskell PW, Altemeier WA. Suppression of Candida albicans by Escherichia coli. J Trauma 1975 ; 15 : 413-8.
19. Hummel RP, Oestreicher EJ, Maley MP, Macmillan BG. Inhibition of Candida albicans by Escherichia coli in vitro and in the germfree mouse. J Surg Res 1973 ; 15 : 53-8.
20. Kennedy MJ, Volz PA. Ecology of Candida albicans gut colonization : inhibition of Candida adhesion, colonization, and dissemination from the gastrointestinal tract by bacterial antagonism. Infect Immun 1985 ; 49 : 654-63.
21. Davis CP, McAllister JS, Savage DC. Microbial colonization of the intestinal epithelium in suckling mice. Infect Immun 1973 ; 7 : 666-72.
22. Field LH, Pope LM, Cole GT, et al. Persistance and spread of Candida albicans after intragastric inoculation of infant mice. Infect Immun 1981 ; 31 : 783-91.
23. Schaedler RW, Dubos R, Costello R. The development of the bacterial flora in the gastrointestinal tract of mice. J Exp Med 1965 ; 122 : 59-66.
24. Samonis G, Anaissie EJ, Bodey GP. Effects of broad-spectrum antimicrobial agents on yeast colonization of the gastrointestinal tracts of mice. Antimicrob Agents Chemother 1990 ; 34 : 2420-2.
25. Pultz N, Stiefel U, Ghannoum M, et al. Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice. Antimicrob Agents Chemother 2005 ; 49 : 438-40.
26. Wingard JR, Dick JD, Merz WG, et al. Pathogenicity of Candida tropicalis and Candida albicans after gastro intestinal inoculation in mice. Infect Immun 1980 ; 29 : 808-13.
27. Crémieux AC, Muller-Serieys C, Panhard X, et al. Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin-clavulanic acid treatments. Antimicrob Agents Chemother 2003 ; 47 : 2030-5.
28. Pecquet S, Chachaty E, Tancrède C, et al. Effects of roxithromycin on fecal bacteria in human volunteers and resistance to colonization in gnotobiotic mice. Antimicrob Agents Chemother 1991 ; 35 : 548-52.
29. Andremont A, Raibaud P, Tancrède C. Effect of erythromycin on microbial antagonism : a study in gnonobiotic mice associated with human fecal flora. J Infect Dis 1983 ; 148 : 579-87.
30. Pecquet S, Andremont A, Tancrède C. Effect of oral ofloxacin on fecal bacteria in human volunteers. Antimicrob Agents Chemother 1987 ; 31 : 124-5.
31. Edluind C, Nord CE. Effect of quinolones on intestinal ecology. Drugs 1999 ; 58 : 65-70.
32. Samonis G, Kofteridis DP, Maraki S, et al. Letters to the editors : levofloxacin and moxifloxacin increase human gut colonization by Candida species. Antimicrob Agents Chemother 2005 ; 49 : 5189.
33. Mavromanolakis E, Maraki S, Cranidis A, et al. The impact of norfloxacin, ciprofloxacin and ofloxacin on human gut colonization by Candida albicans. Scand J Infect Dis 2001 ; 33 : 477-8.
34. Nord CE, Sillerström E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006 ; 50 : 3375-80.
35. Lode H, Von der Höh N, Ziege S, et al. Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis 2001 ; 33 : 899-903.
36. Pletz M, Rau M, Bullita J, et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 2004 ; 48 : 3765-72.
37. Samonis G, Maraki S, Leventakos K, et al. Comparative effects of ertapenem, imipenem, and meropenem on the colonization of the gastrointestinal tract of mice by Candida albicans. Med Mycol 2006 ; 44 : 233-5.
38. Samonis G, Gikas A, Anaissie EJ, et al. Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother 1993 ; 37 : 51-3.
39. Samonis G, Grikas A, Toloudis P, et al. Prospective study of the impact of broad spectrum antibiotics on the yeast flora of the human gut. Eur J Clin Microbiol Infect Dis 1994 ; 13 : 665-9.
40. Mellado E, Cuenca-Estrella M, Regardera J, et al. Sustained gastrointestinal colonisation and systemic dissemination by Candida albicans, Candida tropicalis, and Candida parapsilosis in adult mice. Diag Microbiol Infect Dis 2000 ; 38 : 21-8.
41. Andrutis KA, Riggle PJ, Kumamoto CA, Tzipori S. Intestinal lesions associated with disseminated candidiasis in an experimental animal model. J Clin Microbiol 2000 ; 38 : 2317-23.
42. Sheridan RL, Weber JM, Budkevich LG, et al. Candidemia in the pediatric patient with burns. J Burn Care Rehab 1995 ; 16 : 440-3.
43. Xu J, Sobel JD. Antibiotic-associated vulvovaginal candidiasis. Curr Infect Dis Rep 2003 ; 5 : 481-7.
44. Glover DD, Larsen B. Longitudinal investigation of Candida vaginitis in pregnancy : role of superimposed antibiotic use. Obstet Gynecol 1998 ; 91 : 115-8.
45. Burns DN, Tuomala R, Chang BH, et al. Vaginal colonization or infection with Candida albicans in human immunodeficiency virus-infected women during pregnancy and during post-partum period. Women and Infant Transmission Study Group. Clin Infect Dis 1997 ; 24 : 201-10.
46. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis : a persistent public health problem. Clin Microbiol Rev 2007 ; 20 : 133-63.
47. Eggiman P, Pittet D. Candidiasis among non-neutropenic patients : from colonization to infection. Ann Fr Anest Reanim 2001 ; 20 : 382-8.
48. Wey SB, Mori M, Pfaller MA, et al. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989 ; 149 : 2349-53.
49. Guiot MFL, Febbe WE, Van't Woult JW. Risk factors for fungal infection in patient with malignant hematologic disorder, complication for empirical therapy and prophylaxis. Clin Infect Dis 1994 ; 18 : 525-32.
50. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients : the NEMIS prospective multicenter study. Clin Infect Dis 2001 ; 33 : 177-86.
51. Weese-Maye D, Wheeler Fondriest D, Brouillette R, et al. Risk factors associated with candidemia in the neonatal intensive care unit : a case-control study. Pediatr Infect Dis 1987 ; 6 : 190-6.
52. Lin Y, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia : a case-control study. Antimicrob Agents Chemother 2005 ; 49 : 4555-8.
53. Safdar N, Maki D. The commonamity of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, Enterococcus, Gram-negative bacilli, Clostridium difficile and Candida. Ann Intern Med 2002 ; 136 : 834-44.
54. Richet HM, Andremont A, Tancrede C, et al. Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 1991 ; 13 : 211-5.
55. PaganoL, Antinori A, Ammassari A, et al. Retrospective study of candidemia in patients with haematological malignancies. Clinical features, risk factors and outcome of 76 episodes. Eur J Haematol 1999 ; 63 : 77-85.
56. Sallah S, Wan J, Nguyen NP, et al. Analysis factors related to the occurence of chronic disseminated candidiasis in patients with acute leukemia in a non-bone marrow transplant setting. Cancer 2001 ; 92 : 1349-53.
57. Kromery V, Matejicka F, Pichnova E, et al. Documented fungal infections after prophylaxis or therapy with wide spectrum antibiotics : relationship between certain fungal pathogens and particular antimicrobial? J Chemother 1999 ; 11 : 385-90.
58. Spanik S, Kukuckova E, Pichna P, et al. Analysis of 553 episodes of monomicrobial bacteriemia in cancer patients : any association between risk factors end outcome to particular pathogens ? Sup Care Cancer 1997 ; 5 : 330-3.
59. Kovacicova G, Spanik S, Kunova A, et al. Prospective study of fongemia in a single cancer institution over 10-y period : aetiology, risk factors, consumption of antifungals and outcomes in 140 patients. Scand J Infect Dis 2001 ; 33 : 367-74.
60. Wenzel RP, Gennings C. Bloodstream infections due to Candida species in the intensive care unit : identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 2005 ; 41 : 389-93.
61. Bross J, Talbot GH, Maislin G, et al. Risk factors for nosocomial candidemia : a case-control study in adults without leukemia. Am J Med 1989 ; 87 : 614-20.
62. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neanatl intensive care unit patients. The National Epidemiology of mycosis survey study group. Pediatr Infect Dis J 2000 ; 19 : 319-24.
63. Garcia-San Miguel L, Cobo J, Martos I, et al. Risk factors for candidemia in pediatric patients with congenital heart disease. Infect Control Hosp Epidemiol 2006 ; 27 : 576-80.
64. Nucci M, Colombo AL. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis 2002 ; 21 : 209-11.
65. TIRÉS À PART O. Lortholary